Enveric Biosciences (ENVB) Shares Outstanding (2010 - 2026)
Enveric Biosciences (ENVB) posted Shares Outstanding (Entity) of $1.5 million for Q1 2026, up 351.24% sequentially from $334719.0 in Q4 2025, and up 908.22% YoY from $149809.0 in Q1 2025.
Enveric Biosciences (ENVB) Shares Outstanding (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 908.22% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 908.22% YoY) and the FY2025 annual result came in at $334719.0, up 698.72% from the prior year.
- Shares Outstanding (Entity) grew to $1.5 million in Q1 2026 per ENVB's latest filing, from $334719.0 in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $1.5 million in Q1 2026 and troughed at $4706.0 in Q1 2022.
- A 5-year average of $164465.5 and a median of $22231.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) gained 4.99% in 2023, then surged 908.22% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $8033.0 in 2022, then jumped by 49.32% to $11995.0 in 2023, then soared by 249.37% to $41907.0 in 2024, then surged by 698.72% to $334719.0 in 2025, then soared by 351.24% to $1.5 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.5 million, $334719.0, and $313242.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 445.06 Mn |
| 10 | Enveric Biosciences | 5.50 Mn | -2.79 Mn | - | 3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 334,719.00 |
| Sep 30, 2025 | 313,242.00 |
| Jun 30, 2025 | 216,302.00 |
| Mar 31, 2025 | 149,809.00 |
| Dec 31, 2024 | 41,907.00 |
| Sep 30, 2024 | 48,350.00 |
| Jun 30, 2024 | 42,155.00 |
| Mar 31, 2024 | 22,231.00 |
| Dec 31, 2023 | 11,995.00 |
| Sep 30, 2023 | 12,026.00 |
| Jun 30, 2023 | 11,709.00 |
| Mar 31, 2023 | 11,546.00 |
| Dec 31, 2022 | 8,033.00 |
| Sep 30, 2022 | 9,929.00 |
| Jun 30, 2022 | 5,854.00 |
| Mar 31, 2022 | 4,706.00 |
| Dec 31, 2021 | 2,624.00 |
| Sep 30, 2021 | 2,571.00 |
| Jun 30, 2021 | 2,370.00 |